Company newsCompany release

CVS Health CVS

CVS Health study finds GLP-1 medical savings do not fully offset pharmacy spending at current prices

The company said modeling from the study, across the study population, suggests a net price of approximately $350 per month over three years would bring pharmacy spending and observed medical savings into balance.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

CVS Health released new research on November 15, 2026 that uses real-world data to test whether GLP-1 medicines save enough elsewhere in the health care system to offset their cost. The company said the answer at current prices is not yet.

Using anonymized Aetna claims data from commercial fully insured members, its researchers found GLP-1 use was associated with better clinical outcomes, lower hospital use and lower medical spending compared with matched non-users. The study examined members with index years from 2023 through 2025 and up to three years of follow-up.

Researchers matched GLP-1 users with similar non-users based on age, existing health conditions, prior health care use, and medical and pharmacy spending. The company said the break-even point varies with patients' underlying clinical risk, how long they remain on treatment and how consistently they take their medication.

The company said the findings point to three conditions for getting more value from GLP-1s: treating the right patients, helping people stay on therapy long enough to realize health benefits, and lowering the price. It also said the analysis does not suggest financial break-even should be the sole measure of a medicine's value.

Compton-Phillips said the health benefits are real and that the challenge is making them affordable at scale. The company said she will speak on the topic at the HLTH industry conference in Las Vegas later on November 15, 2026, and that more than 137 million U.S. adults are medically eligible for semaglutide across indications.

Key facts

Modeled break-even net price
Approximately $350 per month over three years, across the study population
Study population
Commercial fully insured Aetna members who used GLP-1s
Follow-up
Up to three years
Adherence measure
Prescriptions covering at least 80% of days
Conference appearance
HLTH, Las Vegas, later on November 15, 2026

All CVS news

Source: The company's release on PR Newswire, November 15, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

CVS Health first, then the newest

All company news